Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Visit Radcliffe Cardiology:

In this insightful interview, Dr David Kandzari (Piedmont Heart Institute, Atlanta, US) joins us to outline the 6-month primary findings of an extension study of the SPYRAL HTN-ON MED Trial (NCT02439775).

SPYRAL HTN aimed to determine the safety and effectiveness of Symplicity Spyral™ multi-electrode renal denervation system (Medtronic) in patients with hypertension and cardiovascular diseases as compared to a sham procedure. This extension trial aims to determine the long-term outcomes of this trial.

This trial demonstrated that despite a significant reduction in Office BP and Win Ratio favoring RDN vs Sham, the primary efficacy endpoint was not met for 24-hr ABPM at 6 months.

Recorded remotely from Atlanta, 2022.
This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Чтобы скачать видео "AHA 22: SPYRAL HTN-ON MED: Renal Denervation in Patients with Hypertension | Dr David Kandzari" передвинте ползунок вправо